Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2019; 9(16):4580-4594. doi:10.7150/thno.34337 This issue Cite

Review

Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity

Marta Tellez-Gabriel1✉, Marie-Françoise Heymann2,3,4, Dominique Heymann2,3,4✉

1. RNA and molecular pathology (RAMP) research group. Department of Medical Biology. The Artic University of Norway (Tromso), Norway.
2. INSERM, European Associated Laboratory “Sarcoma Research Unit”, Department of Oncology and Metabolism, Medical School, University of Sheffield, United Kingdom.
3. INSERM, Institut de Cancérologie de l'Ouest, LabCT, U1232, CRCINA, Université de Nantes, Université d'Angers, 44805 Saint Herblain cedex, France.
4. Institut de Cancérologie de l'Ouest, “Tumor Heterogeneity and Precision Medicine”, 44805 Saint Herblain cedex, France.

✉ Corresponding authors: Dr M. Tellez-Gabriel, e-mail: marta.t.gabrielno or Prof. D. Heymann, e-mail: dominique.heymann

Citation:
Tellez-Gabriel M, Heymann MF, Heymann D. Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics 2019; 9(16):4580-4594. doi:10.7150/thno.34337. https://www.thno.org/v09p4580.htm
Other styles

File import instruction

Abstract

Graphic abstract

Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history of cancer. The present review gives an overview on the origin of tumor heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases.

Keywords: single cell, circulating tumor cell, precision medicine, tumor heterogeneity, omic technologies

Citation styles

APA
Tellez-Gabriel, M., Heymann, M.F., Heymann, D. (2019). Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics, 9(16), 4580-4594. https://doi.org/10.7150/thno.34337.

ACS
Tellez-Gabriel, M.; Heymann, M.F.; Heymann, D. Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics 2019, 9 (16), 4580-4594. DOI: 10.7150/thno.34337.

NLM
Tellez-Gabriel M, Heymann MF, Heymann D. Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics 2019; 9(16):4580-4594. doi:10.7150/thno.34337. https://www.thno.org/v09p4580.htm

CSE
Tellez-Gabriel M, Heymann MF, Heymann D. 2019. Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics. 9(16):4580-4594.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use